Meeting to commence at 9.30 am on Wednesday 10th March 2021 (via Zoom)

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of the previous meeting

5. Chairman’s verbal report

6. AWTTC Work Programme:
   - Medicines Access document in plain language
   - AWTTC work programme consultation 2021/2022
   - AWTTC Communications and Engagement Policy

7. National Prescribing Indicators 2020-21 Q2 Report (for information)
   Introduce Executives from Cardiff & Vale UHB

8. Appraisal 1: Paediatric licence extension submission
   Lurasidone (Latuda®) for the treatment of schizophrenia in adolescents aged 13 years to 17 years

To protect commercial confidentiality the following appraisal will be held in private and all observers will be asked to leave the meeting

9. Appraisal 2: Full submission (Wales Patient Access Scheme)
   Idebenone (Raxone®) for the treatment of visual impairment in adolescent and adult patients with Leber’s hereditary optic neuropathy

10. Reappraisal following request for review on the grounds of ‘Process’
    Appraisal 3: Full submission (Wales Patient Access Scheme)
    Melatonin (Slenyto®) for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient

The outcome of the appraisals will be uploaded to the AWMSG website after the meeting. The applicant company will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AWTTC. AWMSG’s recommendation will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant company or after the ten-day deadline has expired – whichever is sooner. Welsh Government takes account of the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.

Date of next meeting: Tuesday 20th April 2021 commencing 9.30 am